logo
Three R.I. health insurers pay over $1 million in fines for lapses in COVID coverage

Three R.I. health insurers pay over $1 million in fines for lapses in COVID coverage

Yahoo12-06-2025
Three Rhode Island health insurers were fined for charging patients out-of-pocket costs for pandemic-related care, such as emergency room care, doctor visits, and hospital stays, that should have been fully covered, the Office of the Health Insurance Commissioner said. (Getty image)
UnitedHealthcare paid $1 million and two Rhode Island health insurers paid lesser fines for violating state rules for health coverage of COVID-19 services.
Health Insurance Commissioner Cory King announced Thursday that his office had finished collecting fines charged to UnitedHealthcare, Blue Cross & Blue Shield of Rhode Island (BCBSRI) and Aetna. The insurers were penalized for charging patients out-of-pocket costs for pandemic-related care, such as emergency room care, doctor visits, and hospital stays — services that should have been fully covered under a 2021 rule promulgated by Patrick Tigue, King's predecessor in the the Office of the Health Insurance Commissioner (OHIC).
UnitedHealthcare incurred the heaviest fine while Blue Cross and Aetna were fined $20,000 and $10,000, respectively. Consent decrees for the insurance companies stipulated payment was due for UnitedHealthcare and Aetna on June 2, while Blue Cross needed to pay up by June 6. King said Thursday that the final payment was made last week.
'OHIC expects health insurance companies to comply with the law,' King wrote in an email. 'When they do not, they must take corrective actions and face consequences.'
The fines accumulated from July 3, 2021, when the rule was formalized into general law, through May 11, 2023, when Rhode Island's cost waiver rule expired and the COVID-19 public health emergency officially ended.
The cost waiver, however, only applied to fully insured plans, or coverage plans purchased by employers in which the insurer assumes the financial responsibility and risk. The cost mandate did not apply to people receiving services under self-insured plans — the kind of coverage often purchased by larger companies and held by about 60% of covered Rhode Islanders.
The three consent decrees OHIC released Thursday detail the scope of violations and how the insurers fixed their billing problems. UnitedHealthcare's hefty $1 million fine derived from 1,545 claims in which Rhode Island plan members were wrongly charged for COVID-related care. In 2023, the company reprocessed the claims and refunded roughly $270,000 to affected members.
'We are pleased to have resolved this issue with the Rhode Island Office of the Health Insurance Commissioner,' Bradley J. Alexander, a spokesperson for United, said in an email Thursday. 'We remain focused on helping individuals access care while supporting our employees, our network of care providers, our clients and the communities we serve.'
The Blue Cross case was less straightforward. The insurer had already waived cost-sharing for COVID treatment in April 2020, according to spokesperson Rich Salit.
'BCBSRI's cost-share waiver applied to all in-network services and out-of-network services received outside of Rhode Island,' Salit wrote. 'For services in Rhode Island, BCBSRI was encouraging members to seek care from our broad network, as members going out-of-network could still be exposed to provider balance billing.'
Balance billing is when out-of-network providers charge patients for what insurance didn't pay.
According to the consent decree, Blue Cross believed its policy complied with the OHIC statute, at first indicating 'that it was not waiving cost sharing on services related to the treatment of COVID-19 if such services were provided by out-of-network providers within Rhode Island.'
Nevertheless, OHIC did not agree with that interpretation, penalized the company for not covering the out-of-network care in 19 claims. Blue Cross was required to pay $1,751.60 in refunds, plus the $20,000 fine. Salit said the claims came from eight plan members.
'BCBSRI agreed to reimburse the cost sharing those members incurred and updated its policy, and the matter was resolved,' Salit wrote.
Aetna, a subsidiary of CVS, only had three claims flagged under the OHIC rule.
'We are pleased this agreement resolves issues with the OHIC related to three (3) Aetna claims, which we reprocessed in 2022,' Phillip J. Blando, an Aetna spokesperson, wrote via email.
The penalty money goes into the state's general fund, according to OHIC.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AM Best Removes From Under Review With Developing Implications and Affirms Credit Ratings
AM Best Removes From Under Review With Developing Implications and Affirms Credit Ratings

Business Wire

timean hour ago

  • Business Wire

AM Best Removes From Under Review With Developing Implications and Affirms Credit Ratings

BUSINESS WIRE)-- AM Best has removed from under review with developing implications and affirmed the Financial Strength Rating of C (Weak) and the Long-Term Issuer Credit Rating of 'ccc' (Weak) of Health Insurance Plan of Greater New York, EmblemHealth Insurance Company and EmblemHealth Plan, Inc., collectively referred to as Emblem. All companies are subsidiaries of EmblemHealth, Inc. and are domiciled in New York (NY). The outlook assigned to these Credit Ratings (ratings) is stable. The ratings reflect Emblem's balance sheet strength, which AM Best assesses as very weak, as well as its marginal operating performance, neutral business profile and marginal enterprise risk management (ERM). AM Best assesses Emblem's balance sheet strength as very weak, with risk-adjusted capitalization, as measured by Best's Capital Adequacy Ratio (BCAR), also assessed as very weak. Absolute capital and surplus improved slightly in 2024, driven by unrealized capital gains that offset net losses. In the first quarter of 2025, Emblem reported further improvement in its capital and surplus as well as gains from the sale of ConnectiCare operations in the first quarter of 2025, which resulted in more than a $60 million improvement in the capital and surplus at Health Insurance Plan of Greater New York, the lead entity. Emblem's investment portfolio is conservative, with cash and short-term comprising over half of the investment portfolio at year-end 2024. Although capital and surplus improved in 2024 and through first-quarter 2025, Health Insurance Plan of Greater New York, the lead operating entity, remains under a capital restoration plan with the New York State Department of Financial Services. The company is forecasting to restore capital by the end of 2025 and conclude the capital restoration plan. Emblem has a long-term trend of net losses and underwriting losses. However, AM Best acknowledges that results improved through year-end 2024, which continued into the first quarter of 2025. In the first quarter of 2025, Emblem reported a significant reduction in underwriting losses year over year and reported a slight net income for the quarter, which keeps a trend of three consecutive quarters of net income. The neutral business profile reflects Emblem's solid market position in the greater New York City market with a long-standing presence. Additionally, the organization derives a large portion of its membership from union and labor accounts, anchored by the City of New York account. Emblem's ERM is assessed as marginal. While the company has a fully developed ERM program, the organization faced challenges over the years (specifically during Covid periods) in meeting projections and the restoration plan with the New York State Department of Financial Services. Emblem has exceeded the restoration plan projections for the last two years. This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments.

Telehealth Isn't a Luxury — It's a Necessity
Telehealth Isn't a Luxury — It's a Necessity

Medscape

timean hour ago

  • Medscape

Telehealth Isn't a Luxury — It's a Necessity

This transcript has been edited for clarity. Hello, and thank you for joining me today. I'm Dr Alison Kole. I'm boarded in pulmonary critical care and sleep medicine, and I have been practicing for over a decade. I also am the creator and host of the Sleep is My Waking Passion podcast and the medical director of the Oak Health Center Concierge Sleep Telemedicine Program. Today I want to speak directly to you about a critical issue that's occurring in sleep medicine, which is the future of telehealth. There's a lot at stake, and decisions made now will impact patient care for years to come. Some of you may not be aware, but the American Academy of Sleep Medicine [AASM] issued a position statement in February of 2025, urging for the consideration of permanent telehealth services. During the COVID-19 pandemic, emergency waivers allowed for widespread use of telehealth, including coverage for both video- and audio-only visits. This expansion was a lifeline for both patients and providers, and was able to ensure that care continued despite unprecedented times. However, these were temporary waivers and the waivers are set to expire. So, there is a real danger that coverage and reimbursement for telehealth, especially in sleep medicine, could be rolled back. You can think of the AASM's position statement as a call to action. Without permanent coverage in adequate reimbursement, millions could lose access to essential sleep care. And this isn't just a theoretical concern. If telehealth goes away, access will be cut off for many who cannot easily reach in-person services due to a variety of reasons, including geography, mobility, work, or technology barriers. So, why is it that sleep telemedicine is so especially suited to telehealth? There are several reasons for your consideration. Perhaps one of the most obvious reasons is that in order to diagnose sleep disorders, many of us can usually do that without much of a physical exam. Most of our assessments are dependent upon history, sleep diaries, and sleep study data. It's not necessarily a hands-on exam, so this makes remote care both practical and effective in sleep. There's also a couple of other reasons, including our ability to do remote patient monitoring. Most of our CPAP devices allow us to be able to track and see if a patient is being compliant with therapy, but also are they getting effective therapy so that we can triage and make adjustments remotely without the patient needing to come into the office for that. And last but not least, 12% of Americans are living with chronic insomnia in this country. The number-one recommended treatment is cognitive-behavioral therapy for insomnia. This is a series of visits to a behavioral health specialist that can be time-consuming, and there is data that demonstrate that digital cognitive-behavioral therapy for insomnia platforms performs almost equivocally to that of in-person visits. There are several benefits to sleep telehealth access, and these include access, equity, safety, and cost. So, let's get into it. Expanded access: What do I mean? Well, telehealth bridges gaps for rural patients, those with mobility challenges, and people who live far from specialty centers. It also allows sleep specialists, such as myself, to serve patients across state lines. With regard to health equity, audio-only telehealth happens to be crucial for patients without reliable internet or smart devices. Cutting this option would disproportionately harm lower-income, elderly, and rural populations. There's also a patient and public safety issue worth considering. Many sleep patients happen to be at higher risk for drowsy driving. Telehealth eliminates the need for these patients to travel, which directly reduces accident risk. This protects not only the patient but also the public. And lastly, there is an economic value to sleep telemedicine services because treating sleep disorders like obstructive sleep apnea saves the healthcare system billions by preventing complications related to chronic comorbid conditions. These include hypertension, heart disease, and diabetes. Telehealth adds further savings by reducing travel time off from work and no-show rates. If telehealth goes away, you're looking at a loss of access, worsening health disparities, reduced public safety and patient safety, as well as higher costs of care for patients. Telemedicine is not a luxury; it's a necessity for modern, equitable, and effective care. As primary care providers, you play a crucial role in advocating for and utilizing these services to ensure your patients get the care they need when and where they need it. If you'd like to check out the completed episode with my interview featuring Dr K. Praveen Vohra, the lead author of the AASM position statement, please check out my YouTube channel,

UnitedHealth Group confirms DOJ investigation over Medicare billing
UnitedHealth Group confirms DOJ investigation over Medicare billing

Fast Company

time2 hours ago

  • Fast Company

UnitedHealth Group confirms DOJ investigation over Medicare billing

BY UnitedHealth Group says it is cooperating with federal criminal and civil investigations involving its market-leading Medicare business. The health care giant said Thursday that it had contacted the Department of Justice after reviewing media reports about investigations into certain elements of its business. '(UnitedHealth) has a long record of responsible conduct and effective compliance,' the company said in a Securities and Exchange Commission filing. Earlier this year, The Wall Street Journal said federal officials had launched a civil fraud investigation into how the company records diagnoses that lead to extra payments for its Medicare Advantage, or MA, plans. Those are privately run versions of the government's Medicare coverage program mostly for people ages 65 and over. The company's UnitedHealthcare business covers more than 8 million people as the nation's largest provider of Medicare Advantage plans. The business has been under pressure in recent quarters due to rising care use and rate cuts. The Journal said in February, citing anonymous sources, that the probe focused on billing practices in recent months. The paper has since said that a federal criminal health care-fraud unit was investigating how the company used doctors and nurses to gather diagnoses that bolster payments. UnitedHealth said in the filing Thursday that it 'has full confidence in its practices and is committed to working cooperatively with the Department throughout this process.' UnitedHealth Group Inc. runs one of the nation's largest health insurance and pharmacy benefits management businesses. It also operates a growing Optum business that provides care and technology support. UnitedHealth raked in more than $400 billion in revenue last year as the third-largest company in the Fortune 500. Its share price topped $630 last fall to reach a new all-time high. But the stock has mostly shed value since December, when UnitedHealthcare CEO Brian Thompson was fatally shot in midtown Manhattan on his way to the company's annual investor meeting. A suspect, Luigi Mangione, has been charged in connection with the shooting. In April, shares plunged some more after the company cut its forecast due to a spike in health care use. A month later, former CEO Andrew Witty resigned, and the company withdrew its forecast entirely, saying that medical costs from new Medicare Advantage members were higher than expected. The stock price slipped another 3%, or $10.35, to $282.16 in midday trading Thursday. That represents a 55% drop from its all-time high. The Dow Jones Industrial Average, of which UnitedHealth is a component, also fell slightly. Meanwhile, the broader S&P 500 rose. UnitedHealth will report its second-quarter results next Tuesday. —Tom Murphy, AP health writer

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store